Mark Forbes Irving announced as new Managing Director of IDEA Pharma

 

IDEA Pharma is delighted to announce the appointment of Mark Forbes Irving as Managing Director.

Working alongside the company's CEO, Mark will be responsible for driving the next phase of the company's growth plan, overseeing and directing the delivery organisation, ensuring customer service, quality and ongoing product innovation continues to remain at the highest standard as the company expands, taking IDEA and its teams to the next level.

With over 20 years' industry experience, Mark joins the company from Quintiles where he was Director of Health Engagement and Communications, and prior to that, in both industry marketing and consultancy sectors where he has had managing director level experience leading multiple firms. Specialising in change management and directional growth both in EU and USA based businesses, Mark is a highly experienced relationship-based leader with an excellent track record for growing high value, complex enterprise organisations which address the biosector's increasingly complex needs.

"It is great to join a team that truly values unconstrained thinking and that possesses such substantive multidisiplinary experience; this makes a dramatic difference at phase II and throughout the path-to-market journey and delivers maximum product potential. I am delighted to join IDEA at such an exciting time, as it makes the transition into a truly global organisation," said Mark upon his appointment.

Commenting on Mark joining the company, IDEA Pharma's CEO, Mike Rea, said: "We are thrilled to have Mark join us to lead and positively shape the future of our business. With his strong track record in business excellence, we're adding critical skills to our mix, which will be vital as we expand into new markets and help to realise the full significance of our clients' innovations."

Ends

For more information contact:

Jonathan Crosby – Marketing and Communications Director at IDEA Pharma


Email: [email protected]

Telephone: +44 1234 756 343

Mobile: +44 75455 38901

www.ideapharma.com

 

Suggested Articles

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.